Purchase this article with an account.
Joshua L Morgenstern, Anthony Jones, Anne D Strong, Ellen Rhodes, Eric R Williams, Jeffrey L Olson; Polyacrylonitrile implant prevents retinal photoreceptor degeneration in a mouse model of AMD. Invest. Ophthalmol. Vis. Sci. 2020;61(7):322.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Complement levels have been shown to be elevated within the vitreous of patients with Age-related macular degeneration (AMD). It remains unclear whether these elevated levels are an aspect of the disease or a response to it. Regardless, the increased complement levels are a sign of inflammation which leads to tissue damage. We hypothesize a polyacrylonitrile (PAN) based intravitreal implant, with a high affinity for complement, will decrease intraocular complement levels and attenuate complement mediated retinal damage.
Three Complement factor h knockout mice (N=6 eyes), which have previously been shown to have elevated intraocular complement levels, as well as photoreceptor atrophy and declining retinal function, were used as a model for our study. Right eyes (N=3) were given intravitreal PAN injections, and the left eyes (N=3) were used as controls. Serial ERGs were performed on both eyes over the course of two years. Eyes were then enucleated and were prepared for H&E histology. Image Pro was used to analyze cell counts for changes in retinal morphology. A two-tailed Student’s t-test was used for statistical analysis.
ERGs showed significant (p<0.05) loss of a-wave and b-wave amplitude in sham implant and age-matched controls when compared to PAN implanted eyes. H&E histology cell counts demonstrated a significant difference between the control group and the PAN treatment group outer nuclear layer (ONL) (p<0.05) and ganglion cell layers (GCL) (p<0.05) with the control group displaying significant atrophy in the both the ONL and GCL.
PAN implants preserved retinal function and morphology with attenuated photoreceptor atrophy. These findings suggest complement mediated retinal damage as a feature of disease pathology. This novel treatment may offer a therapeutic option for complement driven diseases such as AMD and diabetic retinopathy.
This is a 2020 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only